A Mouse Model for the Transition of Streptococcus pneumoniae from Colonizer to Pathogen upon Viral Co-Infection Recapitulates Age-Exacerbated Illness
September 28th, 2022
4.2K views
This paper describes a novel mouse model for the transition of pneumococcus from an asymptomatic colonizer to a disease-causing pathogen during viral infection. This model can be readily adapted to study polymicrobial and host-pathogen interactions during the different phases of disease progression and across various hosts.
Overview
This study presents a novel mouse model to investigate the transition of pneumococcus from an asymptomatic colonizer to a pathogenic agent during viral infections. This model closely mimics human conditions and can be adapted for studying host-pathogen interactions across various disease phases.
Key Study Components
Area of Science
- Microbiology
- Infectious Diseases
- Immunology
Background
- Pneumococcus can transition from harmless colonization to disease under certain conditions.
- Viral infections can exacerbate pneumococcal diseases, particularly in vulnerable populations.
- Understanding these interactions is crucial for developing targeted therapies.
- The aging population shows increased susceptibility to such infections.
Purpose of Study
- To develop a mouse model that accurately reflects the transition of pneumococcus during viral infections.
- To identify potential therapeutic targets for secondary pneumococcal pneumonia.
- To explore how aging affects host susceptibility to pneumococcal infections.
Methods Used
- Inoculation of mice with pneumococcus and influenza A virus.
- Assessment of bacterial and viral loads in lung tissues.
- Flow cytometry for immune response analysis.
- Biofilm growth assessment in vitro prior to animal studies.
Main Results
- The model successfully mimicked the transition of pneumococcus during viral infection.
- Age-related susceptibility was observed, highlighting the importance of host factors.
- Potential therapeutic targets were identified for further investigation.
- Biofilm growth was effectively monitored and quantified.
Conclusions
- This mouse model is a valuable tool for studying pneumococcal infections.
- It provides insights into the mechanisms of disease progression in aging hosts.
- Future studies can leverage this model to develop targeted therapies for vulnerable populations.
Frequently Asked Questions
What is the significance of the mouse model?
The mouse model allows researchers to study the transition of pneumococcus from a harmless state to a pathogenic one, particularly during viral infections.
How does aging affect susceptibility to pneumococcal infections?
Aging can impair immune responses, making older hosts more susceptible to infections like pneumococcal pneumonia.
What methods were used to assess bacterial loads?
Bacterial loads were assessed through tissue homogenization and plating on blood agar to determine colony-forming units (CFUs).
Why is biofilm growth important in this study?
Biofilm growth is crucial as it represents a key factor in the pathogenicity of pneumococcus and its ability to persist in the host.
What are the potential therapeutic targets identified?
The study aims to identify specific pathways and mechanisms involved in the transition to disease, which could be targeted for therapy.
How can this research impact public health?
By understanding the mechanisms of pneumococcal infections, targeted therapies can be developed to protect vulnerable populations, particularly the elderly.
Executive Industry Relevance
This mouse model enables biopharma teams to dissect the mechanistic transition of Streptococcus pneumoniae from asymptomatic colonizer to pathogen during viral co-infection, directly reflecting human disease progression. By recapitulating age-exacerbated susceptibility and separating colonization from disease onset, the model supports predictive confidence in target validation and therapeutic hypothesis testing. Its design allows for systematic evaluation of host and pathogen genetic variants, informing risk-adjusted portfolio decisions in infectious disease R&D.
Strategic Applications in Biopharma R&D
Early Discovery & Target Validation
- Enables interrogation of host-pathogen interactions underlying the transition from colonization to invasive disease.
- Supports biological de-risking by modeling age-related susceptibility and immune response dynamics.
- Facilitates functional target validation for interventions against secondary bacterial pneumonia.
- Provides a platform for mechanistic studies of genetic variants in both host and pathogen.
Screening & Assay Development
- Establishes validated, reproducible in vivo systems for downstream efficacy and biomarker studies.
- Enables quantitative measurement of bacterial and viral loads, supporting assay standardization.
- Supports screening of candidate therapeutics targeting distinct disease phases.
- Allows for scalable adaptation to test multiple strains and host backgrounds.
Translational & Preclinical Research
- Aligns with disease-relevant models for translational biomarker discovery and validation.
- Provides continuity from mechanistic discovery to preclinical evaluation of anti-infective strategies.
- Enables risk-adjusted advancement of candidates targeting vulnerable populations, such as the aged.
- Supports predictive de-risking by modeling clinically relevant disease exacerbation.
Pipeline & Workflow Integration
This model bridges early discovery, target validation, and preclinical research by enabling hypothesis-driven testing of host-pathogen interactions and therapeutic interventions in a disease-relevant context.
- Discovery Biology: Dissects the mechanistic basis of colonization-to-disease transition and age-related susceptibility.
- Screening: Provides reproducible, quantitative outputs for bacterial and viral burden across experimental arms.
- Analytics: Enables statistical comparison of immune cell influx, pathogen dissemination, and survival outcomes.
- Translational Research: Models clinically relevant exacerbation in aged hosts, supporting biomarker and therapeutic alignment.
- Enterprise Reuse: Adaptable for diverse host and pathogen genetic backgrounds and for studying other polymicrobial interactions.
Operational & Enterprise Impact
- Scientific Value: Increases predictive confidence in target validation and mechanistic de-risking for infectious disease programs.
- Operational Value: Standardizes in vivo workflows for reproducibility and scalability across R&D teams.
- Strategic Value: Informs go/no-go decisions by modeling clinically relevant disease progression and host susceptibility.
- Portfolio Impact: Enables risk-adjusted prioritization of therapeutic candidates targeting secondary bacterial pneumonia.
Implementation Considerations
- Requires expertise in in vivo infectious disease modeling and biofilm culture techniques.
- Demands access to specialized instrumentation for bacterial, viral, and immune cell quantification.
- Necessitates cross-team standardization of inoculation, infection, and analytical protocols.
- Adaptable to various mouse strains and pathogen variants for broader applicability.
- Biofilm growth variability and host age effects must be carefully controlled and validated.
Biopharma FAQs
Why does null hypothesis testing matter for target validation in the co-infection model?
Null hypothesis testing enables teams to rigorously determine whether observed differences in disease progression, immune response, or pathogen dissemination are statistically significant, supporting robust target validation decisions in the context of viral and bacterial co-infection.
How does independent variable isolation fit the discovery pipeline in this mouse model?
By separating colonization and disease induction steps, the model allows precise manipulation of variables such as bacterial strain, viral dose, and host age, facilitating mechanistic de-risking and hypothesis-driven discovery workflows.
What do quantitative dependent variable measurements enable in this workflow?
Quantitative readouts of bacterial and viral loads, immune cell influx, and survival rates provide actionable data for comparing experimental arms, optimizing candidate selection, and informing translational biomarker strategies.
Why are replication requirements critical for cross-functional collaboration in this model?
Replication ensures that findings on host susceptibility, pathogen dissemination, and immune response are robust and reproducible, enabling reliable data sharing and decision-making across discovery, translational, and preclinical teams.
What statistical analysis capabilities are required before implementation of this co-infection model?
Teams must be equipped to perform statistical comparisons of CFU, PFU, immune cell counts, and survival data to validate experimental outcomes and support data-driven advancement of therapeutic hypotheses.
Chapters in this video
0:05
Introduction
0:55
Growing Streptococcus pneumoniae Biofilm
4:15
Intranasal Inoculation of Mice with Biofilm-Grown S. pneumoniae
5:11
Viral Infection with Influenza A Virus (IAV)
6:01
Processing of Infected Tissues for Bacterial Enumeration
8:35
Processing of the Lung Samples for Flow Cytometry
9:07
Results: Enhancement of S. pneumoniae Pathogenicity upon Viral Infection and Advanced Age
11:43
Conclusion
